Clinical Trials Logo

Overactive Bladder clinical trials

View clinical trials related to Overactive Bladder.

Filter by:

NCT ID: NCT05308979 Active, not recruiting - Overactive Bladder Clinical Trials

Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial

Start date: May 1, 2022
Phase: Phase 4
Study type: Interventional

Patients with either overactive bladder (OAB) or urgency urinary incontinence (UUI) with be randomized (like a flip of a coin) to receive 100 units of bladder Botox® at either one injection site or ten injection sites. Efficacy and patient satisfaction will be measured by questionnaires.

NCT ID: NCT05282069 Active, not recruiting - Overactive Bladder Clinical Trials

A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder

Start date: May 12, 2022
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of DA-8010 in patients with overactive bladder.

NCT ID: NCT05256498 Withdrawn - Overactive Bladder Clinical Trials

AURA 1: Augmenting Urinary Reflex Activity: Study 1

AURA1
Start date: April 2022
Phase: N/A
Study type: Interventional

AURA 1 (Augmenting Urinary Reflex Activity: study 1) is a study that evaluates the electrophysiological responses of pudendal nerve stimulation using short-duration extracorporeal stimulation

NCT ID: NCT05250245 Completed - Clinical trials for Obstructive Sleep Apnea

Tolterodine Relieves Overactive Bladder Symptoms in Women With Moderate-to-severe Obstructive Sleep Apnea Syndrome

Start date: June 1, 2020
Phase: Phase 4
Study type: Interventional

In this study, we aim to determine whether combined tolterodine and CPAP therapy is a more effective treatment for patients with OSAS than CPAP treatment only.

NCT ID: NCT05241379 Active, not recruiting - Overactive Bladder Clinical Trials

AURA-2: Augmenting Urinary Reflex Activity

AURA-2
Start date: November 30, 2022
Phase: N/A
Study type: Interventional

AMBER AURA-2 study (Augmenting Urinary Reflex Activity 2) is a short-duration (6 month) safety and electrophysiological study using an implanted Amber UI system and two electrode leads to provide closed-loop pudendal nerve stimulation for the treatment of urinary incontinence.

NCT ID: NCT05240456 Not yet recruiting - Overactive Bladder Clinical Trials

Beta 3 Agonists in Treatment of Non-neurogenic Voiding Dysfunction in Children

Start date: February 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A randomized clinical study to evaluate the safety and efficacy of using the Beta 3 agonist drug (Mirabegron) combined with standard behavioral therapy in comparison to using the anticholinergic drug (Solifenacin) combined with behavioral therapy, for children with non-neurogenic voiding dysfunction refractory to behavioral therapy alone, using improvement of dysfunctional voiding symptom score as a primary measurement of efficacy.

NCT ID: NCT05226286 Active, not recruiting - Overactive Bladder Clinical Trials

Evaluation of Implantable Tibial Neuromodulation Pivotal Study

TITAN 2
Start date: January 31, 2022
Phase: N/A
Study type: Interventional

The purpose of this prospective, multicenter study is to assess the safety and efficacy of tibial neuromodulation using the Medtronic Tibial Neuromodulation (TNM) system.

NCT ID: NCT05200923 Recruiting - Overactive Bladder Clinical Trials

Pelvic Health Electrically Evoked Recording (PEER) 2 Study

PEER 2
Start date: January 18, 2022
Phase: N/A
Study type: Interventional

To collect physiological signals at several timepoints during the therapy evaluation period.

NCT ID: NCT05170100 Completed - Overactive Bladder Clinical Trials

Evaluating a Digital Intervention for Overactive Bladder

Start date: September 1, 2021
Phase: N/A
Study type: Interventional

Overactive Bladder is characterised by (I) Urgency: the sudden and compelling desire to pass urine with or without accidental leakage; (II) Frequency: the need to pass urine far more regularly than is considered normal; and (III) Nocturia: the need to pass urine several times during the night. This study aims to investigate the feasibility, acceptability and preliminary efficacy of a digital intervention (the NUIG OAB App) for overactive bladder. Furthermore, this study will help determine the most appropriate outcomes for use in the future definitive RCT and the effect size for future sample size calculations. Participants will complete an 8-week intervention designed to reduce the symptoms of OAB, delivered through the NUIG OAB App. Participants will be asked to complete online surveys at baseline, 4 weeks and 8 weeks and an in-app Bladder Diary at weeks 1 and 8. There will be no in-person contact with participants by the study team.

NCT ID: NCT05162833 Completed - Overactive Bladder Clinical Trials

Evaluation of the TheraNova Neuromodulation System to Provide Durable Relief of Overactive Bladder Symptoms

Start date: February 20, 2022
Phase: N/A
Study type: Interventional

To evaluate the safety and durability of the TheraNova Neuromodulation System in overactive bladder (OAB) patients.